{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-219580","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-08-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.332355+00:00","generated_at":"2026-06-11T04:16:40.861892+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Taysha Gene Therapies receives FDA Fast Track Designation for TSHA-102 in Rett syndrome","bullets":["FDA granted Fast Track Designation for TSHA-102, an AAV9 gene therapy for Rett syndrome.","TSHA-102 also holds FDA Orphan Drug and Rare Pediatric Disease designations plus EU Orphan Drug.","Phase 1/2 REVEAL adult trial ongoing in Canada; second adult patient expected in current quarter.","FDA cleared IND for pediatric patients; first pediatric dose expected Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-219580","json":"https://secwatch.observer/filing/0001193125-23-219580.json","markdown":"https://secwatch.observer/filing/0001193125-23-219580.md","text":"https://secwatch.observer/filing/0001193125-23-219580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523219580/0001193125-23-219580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523219580/d454718d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:16:40.861892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}